Tumor Immunotherapy
Combination Therapies and Personalized Medicine
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Updated: Jul 5, 2025

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Jun Chen1, Linrong Pang1, Lianxiang He2
1Cancer Chemoradiotherapy Center, The Affiliated People's Hospital of Ningbo University, Ningbo, China.
一名患有复发性子宫癌的患者,缺乏标准生物标志物,对PD-1抑制剂zimberelimab反应良好. 这表明PIK3CA,ErbB2和SMAD4突变可能预测宫癌的免疫治疗反应.
科学领域:
背景情况:
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
15:24Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022